Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 221 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Nivolumab et cancer du rein métastasé en 2e ligne. Prescrire 2017;37:170-1. [Ref.ID 101455]
2.Enlace a cita original
Anónimo. Mechanism target of rapamycin (mTOR): future therapeutic opportunities. Br J Clin Pharmacol 2016;82:1151-403. [Ref.ID 100930]
3. Cita con resumen
Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, Schunkert H, Fusaro M, Kimura T, Kastrati A. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 2016;387:537-44. [Ref.ID 100119]
4. Cita con resumen
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu L-A, Waxman IM, Sharma P, for the CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13. [Ref.ID 99667]
5. Cita con resumen
Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015;385:43-54. [Ref.ID 98725]
6. Cita con resumen
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Fahrni T, Moschovitis A, Noble S, Eberli FR, Wenaweser P, Jüni P, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014;384:2111-22. [Ref.ID 98453]
7. Cita con resumen
Knoll G, Kokolo M, Mallick R, Beck A, Buenaventura C, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekbergh H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014;349:g6679. [Ref.ID 98345]
8. Cita con resumen
Anónimo. Évérolimus et sclérose tubéreuse de Bourneville. Prescrire 2013;33:731. [Ref.ID 96231]
9. Cita con resumen
Anónimo. Évérolimus après transplantation hépatique. Prescrire 2013;33:730. [Ref.ID 96230]
10.Tiene citas relacionadas
Bissler JJ, Kingswood JC, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeler D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-24. [Ref.ID 95086]
11.Tiene citas relacionadas
Sooriakumaran P, Anderson CJ. Everolimus for renal angiomyolipoma in tuberous sclerosis. Lancet 2013;381:783-5. [Ref.ID 95081]
12. Cita con resumen
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-32. [Ref.ID 94767]
13. Cita con resumen
Geoerger B, Blockus H. Everolimus for astrocytomas in tuberous sclerosis complex. Lancet 2013;381:95-6. [Ref.ID 94765]
14. Cita con resumen
Hampton T. Drug linked with diabetes. JAMA 2012;307:2247. [Ref.ID 93180]
16. Cita con resumen
Baselga J, Campone M, Piccart M, Burris III HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lewohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9. [Ref.ID 92340]
17. Cita con resumen
Anónimo. Medicines interactions: the role of P-glycoprotein. Prescriber Update 2011;32:21-2. [Ref.ID 91143]
18. Cita con resumen
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch III JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira Da Silva AM, Lee H-S, Krischer JP, Trapnell BC, for the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleimyomatosis. N Engl J Med 2011;364:1595-606. [Ref.ID 90556]
19.Tiene citas relacionadas
Kaiser C, Pfisterer M. Drug-eluting or bare-metal stents in large coronary arteries. Author/editor response. N Engl J Med 2011;364:1180. [Ref.ID 90518]
20.Tiene citas relacionadas
Aminian A, Lalmand J. Drug-eluting or bare-metal stents in large coronary arteries. N Engl J Med 2011;364:1179. [Ref.ID 90517]
Seleccionar todas
 
 1 a 20 de 221 siguiente >>